

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

UPDATE ON THE PROPOSED TRANSFER OF 100% EQUITY INTEREST IN AN UPSTREAM SHAREHOLDER OF THE COMPANY'S CONTROLLING SHAREHOLDER

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

1. INTRODUCTION

The Board refers to the announcement dated 19 May 2026 made by the Company in relation to the proposed transfer of 100% equity interest in an upstream shareholder of the Company's controlling shareholder (the "**Previous Announcement**"). Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meanings ascribed to them in the Previous Announcement.

As disclosed in the Previous Announcement, on 19 May 2026, the Company was informed by its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) ("**TPH**"), that SIIC Shanghai (Holdings) Co., Ltd. (上海上实(集团)有限公司) ("**SIIC Holdings**") and Shanghai SIIC Investment Development Co., Ltd. (上海上实投资发展有限公司) ("**SIIC Investment Development**") intended to dispose of their entire equity interest in Shanghai Liuliguang Medical Development Co., Ltd. (上海琉璃光医药发展有限公司) ("**Liuliguang Medical**"), representing 100% of the equity interest in Liuliguang Medical, through a public tender process on the Shanghai United Assets and Equity Exchange (上海联合产权交易所) ("**SUAEE**") (the "**Proposed Transfer**"). An information pre-disclosure in respect of the Proposed Transfer was published on the website of the SUAEE for the period from 19 May 2026 to 16 June 2026.

2. UPDATE ON THE PROPOSED TRANSFER

The Board wishes to update shareholders of the Company that, on 24 September 2026, the Company was informed by TPH that the Proposed Transfer had been formally listed on the SUAEE and that the information disclosure in respect of the Proposed Transfer (the "**Information Disclosure**") had commenced, in accordance with the relevant laws and regulations of the People's Republic of China governing transactions of state-owned assets, including the *Measures for the Supervision and Administration of Transactions of State-Owned Assets of Enterprises* (企业国有资产交易监督管理办法), and the applicable transaction rules of the SUAEE.

The Information Disclosure period commenced on 24 September 2026 and will end on 29 October 2026. Further details of the Proposed Transfer are set out in the relevant announcement published on the website of the SUAEE on 24 September 2026, which may be accessed at <https://www.suaee.com/xmzx.html#/Detail?XMID=127420&PLZT=2>.

As at the date of this announcement:

- (a) TPH holds approximately 43.091% of the total issued share capital of the Company and is the direct controlling shareholder of the Company;
- (b) Jinhushen Biological Medical Science and Technology Co., Ltd. (津沪深生物医药科技有限公司) (“**Jinhushen**”) and Tianjin Guoyu Enterprise Management Co., Ltd. (天津国宇企业管理有限公司) hold 67% and 33% of the equity interest in TPH, respectively;
- (c) Liuliguang Medical holds 35% of the equity interest in Jinhushen; and
- (d) SIIC Holdings and SIIC Investment Development hold 51% and 49% of the equity interest in Liuliguang Medical, respectively.

The Company will continue to monitor the progress of the Proposed Transfer closely and will make further announcement(s) as and when appropriate in accordance with applicable laws, regulations and rules.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company, as there is no certainty or assurance as at the date of this announcement that the Proposed Transfer will proceed or be completed.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
24 September 2026